Previous Article | Next Article 
Infection and Immunity, April 1999, p. 2035-2039, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Characterization of Exochelins of the
Mycobacterium bovis Type Strain and BCG Substrains
Jovana
Gobin,1
Diane K.
Wong,2
Bradford W.
Gibson,2 and
Marcus A.
Horwitz1,*
Department of Medicine, School of Medicine,
University of California, Los Angeles, California
90095,1 and Department of Chemistry
and Pharmaceutical Chemistry, University of California, San
Francisco, California 94143-04462
Received 15 May 1998/Returned for modification 16 July
1998/Accepted 13 January 1999
 |
ABSTRACT |
Pathogenic mycobacteria must acquire iron in the host in order to
multiply and cause disease. To do so, they release abundant quantities
of siderophores called exochelins, which have the capacity to scavenge
iron from host iron-binding proteins and deliver it to the
mycobacteria. In this study, we have characterized the exochelins of Mycobacterium bovis, the causative agent
of bovine and occasionally of human tuberculosis, and the
highly attenuated descendant of M. bovis, bacillus
Calmette-Guérin (BCG), widely used as a vaccine against human
tuberculosis. The M. bovis type strain, five substrains of
M. bovis BCG (Copenhagen, Glaxo, Japanese, Pasteur, and
Tice), and two strains of virulent Mycobacterium tuberculosis all produce the same set of exochelins,
although the relative amounts of individual exochelins may
differ. Among these mycobacteria, the total amount of
exochelins produced is greatest in M. tuberculosis,
intermediate in M. bovis, and smallest in M. bovis BCG.
 |
TEXT |
Exochelins are water-soluble iron
siderophores secreted by mycobacteria to scavenge iron from their
extracellular milieu (9, 10). Mycobacteria produce two
general types of exochelins (12). The pathogenic
mycobacteria produce chloroform-soluble exochelins which have a
structure similar to that of mycobactin, another high-affinity
iron-binding molecule of mycobacteria that is water insoluble and is
located in the cell wall (1). The saprophytic mycobacteria
produce chloroform-insoluble exochelins which have a
peptide-like structure (14, 15).
In previous studies, we have isolated and characterized by mass
spectrometry (MS) the exochelins of the pathogenic mycobacteria Mycobacterium tuberculosis and Mycobacterium
avium (7, 20). These mycobactin-like exochelins
contain 3 amino acid residues
2 N-hydroxylysines and 1 serine or threonine. In M. avium, the 3rd amino acid is
always threonine (20). The difference between the
exochelins and mycobactins of the same species resides
exclusively in the R1 side chain (7). In
mycobactins, the R1 side chain is a long-chain fatty acid.
In exochelins, the side chain is a shorter aliphatic chain,
either saturated or unsaturated, that terminates in either a methyl
ester or a carboxylic acid moiety. These differences render the
exochelins more polar than mycobactins and hence water soluble.
Exochelins of the pathogenic mycobacteria are thought to function by
scavenging iron from host iron-binding molecules and transferring the
iron to mycobactins associated with the cell wall. Exochelins of
M. tuberculosis have been shown capable of removing
iron from human transferrin and lactoferrin and donating it to
mycobactins in the cell wall (6).
The exochelins of Mycobacterium bovis and its
attenuated descendant bacillus Calmette-Guérin (BCG) have not
been previously characterized. Therefore, in this study, we sought to
isolate them and characterize them by MS.
M. bovis is a slow-growing pathogenic mycobacterium
that belongs to the M. tuberculosis complex
(M. africanum, M. bovis, M. microti, M. tuberculosis, and M. ulcerans). M. bovis is highly related to
M. tuberculosis on the basis of DNA homology
(19). M. bovis derives its importance from
several factors. First, as the primary causative agent of bovine
tuberculosis, it is of major commercial importance to the
cattle and dairy industry. Second, it can cause human
tuberculosis, mostly via ingestion of unpasteurized cow's milk
(5). With the advent of pasteurization and government programs to eradicate bovine tuberculosis, such cases are now rare in
immunocompetent individuals. However, human immunodeficiency virus-infected persons appear to be at increased risk for such disease (2, 13, 16, 21). Third, M. bovis BCG remains the only available vaccine against tuberculosis.
Although its efficacy has been questioned, the live vaccine has been
administered to nearly 3 billion persons since 1945 (4). BCG
is also administered intravesicularly in the treatment of bladder
cancer. In rare cases, BCG can cause serious and sometimes fatal
disseminated disease in immunocompromised persons (3, 8).
Isolation and purification of M. bovis
exochelins.
We selected for study the M. bovis type strain (ATCC 19210) and five BCG substrains of
different geographic origins that are currently being used by
pharmaceutical companies in vaccines or for research purposes:
Copenhagen (ATCC 27290), Glaxo (ATCC 35741), Japanese (ATCC
35737), Pasteur (ATCC 35734), and Tice (ATCC 35743). To
obtain exochelins of M. bovis and
M. bovis BCG, we cultured the bacteria in modified
iron-deficient Sauton's broth medium (1 µM iron; no Tween) in
1.9-liter tissue culture flasks, 300 ml per flask, without shaking at
37°C in 5% CO2-95% air for 3 to 8 weeks
(7). All bacteria were grown in iron-deficient medium to
enhance exochelin production, from an
A540 of 0.05 to an A540 of >1. We purified the exochelins at a point at which
production was maximal
6 weeks for M. tuberculosis and
8 weeks for M. bovis
as previously described
(7). Briefly, the supernatant fluid was saturated with iron,
and ferri-exochelins were extracted into chloroform. The
chloroform extract was dried, and the exochelins were purified
by reverse-phase high-pressure liquid chromatography (HPLC) on a
C18 column (Vydac, Western Analytical, Temecula, Calif.) with a 50 to 100% gradient of buffer B (0.1% trifluoroacetic
acid-50% acetonitrile) at a flow rate of 1 ml/min. Individual
exochelins were further purified on an alkyl phenyl column
(Waters, Bedford, Mass.) by using the same buffers and flow rate.
MS analysis of exochelins.
Peaks isolated from the
HPLC and identified as potential exochelins were first
subjected to mass analysis by matrix-assisted laser desorption
ionization MS. For these experiments, a Voyager linear time-of-flight
(TOF) mass spectrometer (PerSeptive Biosystems, Framington, Mass.)
equipped with a 337-nm N2 laser was used. M. bovis exochelins were analyzed under delayed-extraction
conditions as described by Vestal et al. (17). The improved
optics of delayed extraction allowed for increased resolving power
(1,500 M/
M) and isotopic resolution of the exochelin
molecular ions. Data were recorded with a 500-MHz digitizer. Samples
were concentrated under a vacuum, and small aliquots (1 ml) were mixed
1:1 with the matrix (a saturated solution of
-cyano-4
hydroxycinnamic acid in 70% acetonitrile-0.1% trifluoroacetic
acid). The instrument was externally calibrated by using a
mixture of standard peptides consisting of angiotensin II and bombesin.
The exochelins of M. bovis were further
analyzed by collision-induced dissociation (CID) on an Autospec EBE
orthogonal acceleration TOF mass spectrometer (Micromass Inc.,
Manchester, United Kingdom) equipped with a N2 laser (337 nm). After the MS-1 was tuned manually to transmit the C-12
monoisotopic ion of the precursor mass, a two-stage deceleration
electrostatic lens focused the ions into an approximately parallel beam
before they entered the gas collision cell. The collision cell was
filled with Xe gas with a collision energy of 800 eV. Voltage applied
periodically from a push-out electrode extracted the precursor and
product ions into a linear TOF mass analyzer. All spectra were recorded
with a microchannel plate detector using a time-to-digital converter
(Precision Instruments, Knoxville, Tenn.) (11). Small
aliquots of sample (1 µl) were mixed 1:1 with the matrix (a
saturated solution of 2,5-dihydroxybenzoic acid in acetone). The CID
spectra were calibrated by using fragment ions formed from a
standard peptide (Renin).
The exochelins of
M. bovis BCG were also
analyzed by tandem MS, but in this case under liquid secondary
ionization MS (LSIMS)
with a four-sector mass spectrometer (Kratos
Concept II HH; Kratos
Analytical, Manchester, United Kingdom) as
previously described
(
7). Small aliquots of the sample (1 to
5 µl) were transferred
to the LSIMS probe along with 1 µl of a
thioglycerol-glycerol
(1:1, vol/vol) matrix. The collision cell was
filled with He and
floated at 2 keV for a collision energy of 6 keV.
Samples were
ionized by using an LSIMS source operating with
Cs
+ in the positive-ion mode. In each case, the positive
desferri
molecular ion, (M+H)
+, was selected in MS-1 for
analysis. All spectra were recorded
and mass assigned by using a
scanning array detector and a Mach3
data system (
18).
Characterization of the exochelins of M. bovis and M. bovis BCG.
As with
M. tuberculosis Erdman and H37Ra, the chloroform
extract of the culture filtrate of the M. bovis type
strain contained a large family of exochelins. More than 20 peaks exhibiting a high A450 eluted from the
C18 reverse-phase HPLC column (Fig. 1). Based on the similarity of their
elution pattern to that of exochelins from M. tuberculosis (Fig. 1) (7), we tentatively identified 18 of these peaks as ferri-exochelins and
subsequently confirmed that they were exochelins by MS analysis
(only the major peaks were analyzed). The patterns of elution were very
similar at 3, 6, and 8 weeks of culture (data not shown). The yield was highest at 8 weeks (750 µg/liter).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Elution profile of an 8-week culture filtrate from the
M. bovis type strain (top) and of a 6-week culture
filtrate from M. tuberculosis Erdman (bottom) on a
C18 reverse-phase HPLC column. The chloroform extract of 1 liter of the M. bovis culture filtrate or 750 ml of the
M. tuberculosis culture filtrate was loaded onto the
column. Iron-binding molecules were monitored at 450 nm. The dashed
line in each graph represents the concentration of buffer B. Each
labeled peak was analyzed by MS and shown to contain an
exochelin. Exochelin designations are given above each peak
(see the legend to Fig. 3).
|
|
Most of the
M. bovis exochelins were found in
M. tuberculosis, but they differed in relative
abundance. The two most abundant
exochelin species of
M. bovis, 772TM and 786TM (designated according
to the
nomenclature for exochelins described in the legend to
Fig.
3),
are not the most abundant in
M. tuberculosis but are
still among the top 10 in abundance. The third most abundant
M. bovis exochelin species, 772TC, has not been
identified in
M. tuberculosis. Two other
exochelin species of
M. bovis
814TC and
800TM

have also not yet been found in
M. tuberculosis.
All five substrains of
M. bovis BCG produced the same
set of exochelins (Fig.
2). The
overall yields of exochelins from the
BCG strains were
comparatively low

75 µg/liter for BCG Glaxo,
140 µg/liter for BCG
Copenhagen, 150 µg/liter for BCG Japanese,
345 µg/liter for
BCG Pasteur, and 390 µg/liter for BCG Tice versus
750 µg/liter for
the
M. bovis type strain and 2 to 4 mg/liter
for
M. tuberculosis. Furthermore, there was great variation
in
the relative quantities of individual exochelins. However,
exochelins
772TM, 800SC, and 814SC were the major species of
all BCG strains.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Elution profiles of 8-week culture filtrates from
M. bovis BCG Copenhagen, Glaxo, Japanese, Pasteur, and
Tice on a C18 reverse-phase HPLC column. The chloroform
extract of 250 ml of each culture filtrate was loaded onto the column.
Iron-binding molecules were monitored at 450 nm. Peaks 1, 2, and 3 correspond to exochelins 772TM, 800SC, and 814SC,
respectively.
|
|
Based on the elution times after HPLC separation and the MS mass
and fragmentation data on individual exochelins, the
M. bovis,
M. bovis BCG, and
M. tuberculosis Erdman and H37Ra exochelins
appear to be structurally identical. As in the case of
M. tuberculosis,
the core structures of the exochelins of
M. bovis and
M. bovis BCG are identical
to those of the mycobactins of the same species
and contain 3 amino
acid moieties

2
N-hydroxylysines and either
a serine or a
threonine, depending on the absence or the presence
of a methyl group
at R
3 (Fig.
3). This core
contains the functional
groups that bind the iron atom. As with
M. tuberculosis and
M. avium, the
difference between the exochelins and mycobactins of
M. bovis resides exclusively in the R
1 side
group. The R
1 side
chains of the
M. bovis
exochelins are either saturated or unsaturated
and terminate
with either a methyl ester or a carboxylic acid,
as previously
described for
M. tuberculosis (
7) and
M. avium (
20).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
General structure of exochelins of the
M. bovis type strain. The exochelins of
M. bovis differ from each other at R1 and
R3. R1 is either saturated or singly
unsaturated and terminates with either a methyl ester
(COOCH3) or a carboxylic acid (COOH) moiety. R3
is either H or CH3. The exochelins of M. bovis and M. tuberculosis display the same
variations at R1 and R3 and also are identical
at R4 and R5. The exochelins of
M. avium display the same variations at R1
as M. bovis and M. tuberculosis, but
R3 is always CH3. In addition, M. avium differs from the other two species at R4, which
is CHCH2CH3, and R5, which is
CHCH3. The exochelins are named according to (i)
their mass in daltons in the iron-loaded form, (ii) whether
R3 is H (serine) (S) or CH3 (threonine) (T),
and (iii) whether R1 terminates in a methyl ester (M) or
carboxylate (C) moiety.
|
|
Conclusions.
This study demonstrates that the pathogenic
mycobacteria M. tuberculosis and M. bovis produce the same set of iron-binding exochelins.
Moreover, BCG, an attenuated strain of M. bovis,
produces the same set of exochelins as the pathogenic
mycobacteria M. tuberculosis and M. bovis. There are only two differences between the
exochelins of M. tuberculosis and M. bovis among the strains studied. One difference is in the overall
amount of exochelins produced: greatest in M. tuberculosis, intermediate in M. bovis, and
smallest in M. bovis BCG. The second difference is in
the relative amounts of specific exochelin species produced, as
each mycobacterial species and strain has its own unique pattern of
exochelin production.
 |
ACKNOWLEDGMENTS |
This work was supported by grant AI35275 from the National
Institutes of Health and by grant R96-LA1302/SF1301 from the California Universitywide AIDS Research Program. J. Gobin was supported by a
fellowship from The Will Rogers Memorial Fund, and D. K. Wong was
supported by a fellowship from The American Foundation for Pharmaceutical Education. We are indebted to PerSeptive Biosystems for
the generous loan of the Voyager instrument to UCSF and to the UCSF
Mass Spectrometry facility, which is partially supported by the
National Center for Research Resources (RR 01614).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, CHS 37-121, UCLA School of Medicine, 10833 LeConte Ave., Los Angeles, CA 90095. Phone: (310) 206-0074. Fax: (310) 794-7156. E-mail:
MHorwitz{at}med1.medsch.ucla.edu.
Editor:
P. J. Sansonetti
 |
REFERENCES |
| 1.
|
Barclay, R., and C. Ratledge.
1988.
Mycobactins and exochelins of Mycobacterium tuberculosis, M. bovis, M. africanum and other related species.
J. Gen. Microbiol.
134:771-776[Abstract/Free Full Text].
|
| 2.
|
Bouvet, E.,
E. Casalino,
G. Mendoza-Sassi,
S. Lariven,
E. Valle,
M. Pernet,
S. Gottot, and F. Vachon.
1993.
A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients. A case-control study.
AIDS
7:1453-1460[Medline].
|
| 3.
|
Casanova, J. L.,
S. Blanche,
J.-F. Emile,
E. Jouanguy,
S. Lamhamedi,
F. Altare,
J.-L. Stéphan,
F. Bernaudin,
P. Bordigoni,
D. Turck,
A. Lachaux,
M.-A. Pocidalo,
F. Le Deist,
J.-L. Gaillard,
C. Griscelli, and A. Fischer.
1996.
Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study.
Pediatrics
98:774-778[Abstract/Free Full Text].
|
| 4.
|
Colditz, G. A.,
T. F. Brewer,
C. S. Berkey,
M. E. Wilson,
E. Burdick,
H. V. Fineberg, and F. Mosteller.
1994.
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.
JAMA
271:698-702[Abstract/Free Full Text].
|
| 5.
|
Danker, W. M.,
N. J. Waecker,
M. A. Essey,
K. Moser,
M. Thompson, and C. Davis.
1993.
Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen.
Medicine
72:11-37[Medline].
|
| 6.
|
Gobin, J., and M. A. Horwitz.
1996.
Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall.
J. Exp. Med.
183:1527-1532[Abstract/Free Full Text].
|
| 7.
|
Gobin, J.,
C. H. Moore,
J. R. Reeve, Jr.,
D. K. Wong,
B. W. Gibson, and M. A. Horwitz.
1995.
Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins.
Proc. Natl. Acad. Sci. USA
92:5189-5193[Abstract/Free Full Text].
|
| 8.
|
Lotte, A.,
O. Waz-Höcket,
N. Poisson,
N. Dumitrescu,
M. Verron, and M. Couvet.
1984.
BCG complications.
Adv. Tuberc. Res.
21:107-245[Medline].
|
| 9.
|
Macham, L. P., and C. Ratledge.
1975.
A new group of water soluble iron-binding compounds from mycobacteria: exochelins.
J. Gen. Microbiol.
89:379-382[Free Full Text].
|
| 10.
|
Macham, L. P.,
C. Ratledge, and J. C. Nocton.
1975.
Extracellular iron acquisition by mycobacteria: role of the exochelins and evidence against the participation of mycobactin.
Infect. Immun.
12:1242-1251[Abstract/Free Full Text].
|
| 11.
|
Medzihradszky, K. F.,
D. A. Maltby, et al.
1997.
Protein sequence and structural studies employing matrix-assisted laser desorption ionization-high energy collision-induced dissociation.
Int. J. Mass Spectrom. Ion Processes
160:357-369.
|
| 12.
|
Ratledge, C.
1984.
Metabolism of iron and other metals by mycobacteria, p. 603-627.
In
G. P. Kubica, and L. G. Wayne (ed.), The Mycobacteria: a sourcebook. Marcel Dekker, New York, N.Y.
|
| 13.
|
Samper, S.,
C. Martin,
A. Pinedo,
A. Rivero,
J. Blásquez,
F. Baquero,
D. van Soolingen, and J. van Embden.
1997.
Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis.
AIDS
11:1237-1242[Medline].
|
| 14.
|
Sharman, G. J.,
D. H. Williams,
D. F. Ewing, and C. Ratledge.
1995.
Determination of the structure of exochelin MN, the extracellular siderophore from Mycobacterium neoaurum.
Chem. Biol.
2:553-561[Medline].
|
| 15.
|
Sharman, G. J.,
D. H. Williams,
D. F. Ewing, and C. Ratledge.
1995.
Isolation, purification and structure of exochelin MS, the extracellular siderophore from Mycobacterium smegmatis.
Biochem. J.
305:187-196.
|
| 16.
|
van Soolingen, D.,
P. E. W. de Haas,
J. Haagsma,
T. Eger,
P. W. M. Hermans,
V. Ritacco,
A. Alito, and J. D. A. van Embden.
1994.
Use of various genetic markers in differentiation of Mycobacterium bovis strains from animals and humans and for studying epidemiology of bovine tuberculosis.
J. Clin. Microbiol.
32:2425-2433[Abstract/Free Full Text].
|
| 17.
|
Vestal, M. L.,
P. Juhasz, et al.
1995.
Delayed extraction matrix-assisted laser desorption time-of-flight mass spectrometry.
Rapid Commun. Mass Spectrom.
9:1044-1050.
|
| 18.
|
Walls, F. C.,
M. A. Baldwin, et al.
1990.
Experience with multichannel array detection in tandem mass spectrometric characterization of biopolymers at the picomole level, p. 197-216.
In
A. L. Burlingame, and J. A. McCloskey (ed.), Biological mass spectrometry. Elsevier, Amsterdam, The Netherlands.
|
| 19.
|
Wayne, L. G.
1984.
Mycobacterial speciation, p. 25-65.
In
G. P. Kubica, and L. G. Wayne (ed.), The Mycobacteria: a sourcebook. Marcel Dekker, New York, N.Y.
|
| 20.
|
Wong, D. K.,
J. Gobin,
M. A. Horwitz, and B. W. Gibson.
1996.
Characterization of exochelins of Mycobacterium avium: evidence for saturated and unsaturated and for acid and ester forms.
J. Bacteriol.
178:6394-6398[Abstract/Free Full Text].
|
| 21.
|
World Health Organization.
1994.
Zoonotic tuberculosis (Mycobacterium bovis) memorandum from WHO meeting (with participation of FAO).
Bull. W. H. O.
72:851-857[Medline].
|
Infection and Immunity, April 1999, p. 2035-2039, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Aguirre-Blanco, A. M., Lukey, P. T., Cliff, J. M., Dockrell, H. M.
(2007). Strain-Dependent Variation in Mycobacterium bovis BCG-Induced Human T-Cell Activation and Gamma Interferon Production In Vitro. Infect. Immun.
75: 3197-3201
[Abstract]
[Full Text]
-
Olakanmi, O., Schlesinger, L. S., Britigan, B. E.
(2007). Hereditary hemochromatosis results in decreased iron acquisition and growth by Mycobacterium tuberculosis within human macrophages. J. Leukoc. Biol.
81: 195-204
[Abstract]
[Full Text]
-
LaMarca, B. B. D., Zhu, W., Arceneaux, J. E. L., Byers, B. R., Lundrigan, M. D.
(2004). Participation of fad and mbt Genes in Synthesis of Mycobactin in Mycobacterium smegmatis. J. Bacteriol.
186: 374-382
[Abstract]
[Full Text]
-
Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H. M., Harris, A. L.
(2002). A Mycobacterial Iron Chelator, Desferri-Exochelin, Induces Hypoxia-inducible Factors 1 and 2, NIP3, and Vascular Endothelial Growth Factor in Cancer Cell Lines. Cancer Res.
62: 6924-6927
[Abstract]
[Full Text]
-
RAJIV, J., DAM, T., KUMAR, S., BOSE, M., AGGARWAL, K.K., BABU, C.R.
(2001). Inhibition of the in-vitro growth of Mycobacterium tuberculosis by a phytosiderophore. J Med Microbiol
50: 916-918
[Abstract]
[Full Text]
-
De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y., Barry, C. E. III
(2000). The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. USA
97: 1252-1257
[Abstract]
[Full Text]